Paper36959353
Optimizing human α-galactosidase for treatment of Fabry disease.
Hallows WC and 18 others. Sci Rep, 2023. Cited by 14 papers, by iCite.
Cite this record
ConductScience Library. Optimizing human α-galactosidase for treatment of Fabry disease. Papers, record 36959353. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36959353
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics8
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Fabry Disease | Major topic |
| Humans | |
| Mice | |
| Animals | |
| alpha-Galactosidase | |
| Kidney | |
| Disease Models, Animal | |
| Fibroblasts |
Source PubMed
References65
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 31836927 | Impact of the organic cation transporter 2 inhibitor cimetidine on the single-dose pharmacokinetics of the glucosylceramide synthase inhibitor lucerastat in healthy subjects. | Eur J Clin Pharmacol | 2020 | https://conductscience.org/library/papers/31836927 | PubMed |
| 2 | 31951773 | In silico identification and modification of T cell epitopes in pertussis antigens associated with tolerance. | Hum Vaccin Immunother | 2020 | https://conductscience.org/library/papers/31951773 | PubMed |
| 3 | 11758673 | Natural history of Fabry disease in affected males and obligate carrier females. | J Inherit Metab Dis | 2001 | https://conductscience.org/library/papers/11758673 | PubMed |
| 4 | 27555236 | Fabry Disease: A Disorder of Childhood Onset. | Pediatr Neurol | 2016 | https://conductscience.org/library/papers/27555236 | PubMed |
| 5 | 20345279 | New strategies for enzyme replacement therapy for lysosomal storage diseases. | Rejuvenation Res | 2010 | https://conductscience.org/library/papers/20345279 | PubMed |
| 6 | 22195554 | The molecular basis of pharmacological chaperoning in human α-galactosidase. | Chem Biol | 2011 | https://conductscience.org/library/papers/22195554 | PubMed |
| 7 | 26310963 | Mannose receptor-mediated delivery of moss-made α-galactosidase A efficiently corrects enzyme deficiency in Fabry mice. | J Inherit Metab Dis | 2016 | https://conductscience.org/library/papers/26310963 | PubMed |
| 8 | 27523577 | Relative distribution of Gb3 isoforms/analogs in NOD/SCID/Fabry mice tissues determined by tandem mass spectrometry. | Bioanalysis | 2016 | https://conductscience.org/library/papers/27523577 | PubMed |
| 9 | 29880732 | A Liquid Chromatography-Quadrupole-Time-of-Flight Mass Spectrometric Assay for the Quantification of Fabry Disease Biomarker Globotriaosylceramide (GB3) in Fabry Model Mouse. | Pharmaceutics | 2018 | https://conductscience.org/library/papers/29880732 | PubMed |
| 10 | 30198337 | MAPPs for the identification of immunogenic hotspots of biotherapeutics; an overview of the technology and its application to the biopharmaceutical arena. | Expert Rev Proteomics | 2018 | https://conductscience.org/library/papers/30198337 | PubMed |
| 11 | 2357375 | Gene splicing by overlap extension: tailor-made genes using the polymerase chain reaction. | Biotechniques | 1990 | https://conductscience.org/library/papers/2357375 | PubMed |
| 12 | 30834538 | Pegunigalsidase alfa, a novel PEGylated enzyme replacement therapy for Fabry disease, provides sustained plasma concentrations and favorable pharmacodynamics: A 1-year Phase 1/2 clinical trial. | J Inherit Metab Dis | 2019 | https://conductscience.org/library/papers/30834538 | PubMed |
| 13 | 17224688 | Heterozygous Fabry women are not just carriers, but have a significant burden of disease and impaired quality of life. | Genet Med | 2007 | https://conductscience.org/library/papers/17224688 | PubMed |
| 14 | 19853240 | Use of a modified alpha-N-acetylgalactosaminidase in the development of enzyme replacement therapy for Fabry disease. | Am J Hum Genet | 2009 | https://conductscience.org/library/papers/19853240 | PubMed |
| 15 | 32274449 | Current and Investigational Therapeutics for Fabry Disease. | Kidney Int Rep | 2020 | https://conductscience.org/library/papers/32274449 | PubMed |
| 16 | 32738442 | Prediction of improved therapeutics for fabry disease patients generated by mutagenesis of the α-galactosidase A active site, dimer interface, and glycosylation region. | Protein Expr Purif | 2020 | https://conductscience.org/library/papers/32738442 | PubMed |
| 17 | 29698600 | Development and Analytical Characterization of Pegunigalsidase Alfa, a Chemically Cross-Linked Plant Recombinant Human α-Galactosidase-A for Treatment of Fabry Disease. | Bioconjug Chem | 2018 | https://conductscience.org/library/papers/29698600 | PubMed |
| 18 | 26597321 | Immune response to enzyme replacement therapies in lysosomal storage diseases and the role of immune tolerance induction. | Mol Genet Metab | 2016 | https://conductscience.org/library/papers/26597321 | PubMed |
| 19 | 27834756 | Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study. | J Med Genet | 2017 | https://conductscience.org/library/papers/27834756 | PubMed |
| 20 | 19846852 | X-linked thrombophilia with a mutant factor IX (factor IX Padua). | N Engl J Med | 2009 | https://conductscience.org/library/papers/19846852 | PubMed |
Cited by12
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 14 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42344794 | Case Report: Is it COPD? It is Fabry disease: a case in which bronchodilators were briefly used but not continued, prioritizing enzyme replacement therapy. | Front Pharmacol | 2026 | https://conductscience.org/library/papers/42344794 | PubMed |
| 42292401 | Review: application and opportunities for machine learning and artificial intelligence in preclinical immunogenicity risk assessment. | Front Immunol | 2026 | https://conductscience.org/library/papers/42292401 | PubMed |
| 42211051 | Pathophysiological mechanisms of organ injury in Fabry disease: Update via multi-omics. | Genes Dis | 2026 | https://conductscience.org/library/papers/42211051 | PubMed |
| 41712507 | Catalyzing Carbohydrate Cleavage: Glycosidases and Their Mechanisms. | Chem Rev | 2026 | https://conductscience.org/library/papers/41712507 | PubMed |
| 41171875 | One SQ HEDGES DNA vector only dose produces durable hGLA or anti-SARS-CoV-2 mAb therapeutic serum protein levels. | PLoS One | 2025 | https://conductscience.org/library/papers/41171875 | PubMed |
| 40762941 | Galacto-oligosaccharides enrich galactosidase-encoded rather than all Lachnospiraceae bacteria to redress abnormal gut microbiota and lipid metabolism in pregnancy. | Sci China Life Sci | 2026 | https://conductscience.org/library/papers/40762941 | PubMed |
| 40420145 | Current status of the immunogenicity of enzyme replacement therapy in fabry disease. | Orphanet J Rare Dis | 2025 | https://conductscience.org/library/papers/40420145 | PubMed |
| 40149554 | Reversing Pathology in an Aggravated Fabry Mouse Model Using Low-Dose Engineered Human Alpha-Galactosidase A AAV Gene Therapy. | Biomedicines | 2025 | https://conductscience.org/library/papers/40149554 | PubMed |
| 39687734 | Preclinical efficacy and safety of adeno-associated virus 5 alpha-galactosidase: A gene therapy for Fabry disease. | Mol Ther Methods Clin Dev | 2024 | https://conductscience.org/library/papers/39687734 | PubMed |
| 39468034 | Dirichlet latent modelling enables effective learning and sampling of the functional protein design space. | Nat Commun | 2024 | https://conductscience.org/library/papers/39468034 | PubMed |
| 38667321 | Flow Cytometry-Based Assay to Detect Alpha Galactosidase Enzymatic Activity at the Cellular Level. | Cells | 2024 | https://conductscience.org/library/papers/38667321 | PubMed |
| 38371570 | Fresh Baked: An Overview of Newly FDA-Approved Drugs for Dermatological Usage. | Indian J Dermatol | 2023 | https://conductscience.org/library/papers/38371570 | PubMed |
Genes11
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| A4GALT | 53947 | PubTator's text mining | https://conductscience.org/library/genes/53947 | NCBI Gene |
| CD4 | 920 | PubTator's text mining | https://conductscience.org/library/genes/920 | NCBI Gene |
| CD8A | 925 | PubTator's text mining | https://conductscience.org/library/genes/925 | NCBI Gene |
| F9 | 2158 | PubTator's text mining | https://conductscience.org/library/genes/2158 | NCBI Gene |
| GLA | 2717 | PubTator's text mining | https://conductscience.org/library/genes/2717 | NCBI Gene |
| HLA-A | 3105 | PubTator's text mining | https://conductscience.org/library/genes/3105 | NCBI Gene |
| HLA-C | 3107 | PubTator's text mining | https://conductscience.org/library/genes/3107 | NCBI Gene |
| HLA-DRB1 | 3123 | PubTator's text mining | https://conductscience.org/library/genes/3123 | NCBI Gene |
| M6PR | 4074 | PubTator's text mining | https://conductscience.org/library/genes/4074 | NCBI Gene |
| PDE6B | 5158 | PubTator's text mining | https://conductscience.org/library/genes/5158 | NCBI Gene |
| UGCG | 7357 | PubTator's text mining | https://conductscience.org/library/genes/7357 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36959353
GET https://conductscience.org/api/papers/v1/36959353/references?page=2